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A
 
BSTRACT
Background:
 
Recently, a second prostaglandin D
 
2
 
(PGD
 
2
 
) receptor, chemoattractant receptor-homologous
molecule expressed on Th2 cells (CRTH2), was identi-
fied. Because PGD
 
2
 
 was reported to have chemotactic
activity on eosinophils, CRTH2 expressed on eosi-
nophils attracted interest as a receptor associated with
eosinophil migration to, and accumulation at, inflam-
matory sites. To elucidate the mechanism regulating
the expression of CRTH2 on eosinophils, the effects of
PGD
 
2
 
, interleukin (IL)-4, IL-5 and interferon (IFN)-
 
γ
 
 on
CRTH2 expression were investigated.
 
Methods:
 
Blood eosinophils were purified using Percoll
and anti-CD16 antibody coated magnetic beads. Eosi-
nophils were incubated with PGD
 
2
 
 and/or IL-4, IL-5
and IFN-
 
γ
 
. The expression of CRTH2 on eosinophils
was measured using a FACScan cytometer (Becton
Dickinson Immunocytometry Systems, San Jose, CA,
USA).
 
Results:
 
Prostaglandin D
 
2
 
 and IL-5, but not IL-4 and
IFN-
 
γ
 
, downregulated the expression of CRTH2 on
eosinophils. Furthermore, PGD
 
2
 
- and IL-5-induced
downregulation of CRTH2 on human eosinophils was
inhibited by phenylarsine oxide, a receptor internaliza-
tion inhibitor.
 
Conclusions:
 
These results suggest that PGD
 
2
 
 and
IL-5 regulate CRTH2 expression on eosinophils through
CRTH2 internalization. The decreased expression of
CRTH2 on tissue eosinophils may make these cells
remain at the site of allergic inflammation.
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I
 
NTRODUCTION
 
Allergic inflammation is characterized by the selective
accumulation of inflammatory cells, such as activated
Th2 lymphocytes and eosinophils. The Th2 cells, as well
as eosinophils, play an essential role in the pathogenesis
of allergic inflammation.
 
1,2
 
 Phenotypic characterization
of Th2 cells has become a focus of interest. Chemo-
attractant receptor-homologous molecule expressed on
Th2 cells (CRTH2) was recently cloned as a Th2-
selective surface molecule distinguished from Th1 cells.
 
3
 
It was also found that CRTH2 was expressed on eosi-
nophils in addition to Th2 cells.
 
4
 
Interestingly, CRTH2 was recently identified as a
second receptor for prostaglandin D
 
2
 
 (PGD
 
2
 
).
 
5
 
 Prosta-
glandin D
 
2
 
 is a major arachidonic acid metabolite
released by antigen-activated mast cells
 
6
 
 and Th2 cells.
 
7
 
Large amounts of PGD
 
2
 
 are generated in the asthmatic
lung.
 
8,9
 
 Prostaglandin D
 
2
 
 and CRTH2 may be implicated
in the pathogenesis of allergic diseases.
The mechanism by which CRTH2 expression is regu-
lated is unclear. Therefore, in the present study, the
modulation of surface CRTH2 expression on human
eosinophils by PGD
 
2
 
, Th2 cytokines (such as interleukin
(IL)-4 and IL-5)and Th1 cytokines (such as interferon
(IFN)-
 
γ
 
), was investigated.
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M
 
ETHODS
 
Eosinophil purification
 
Peripheral venous blood was obtained from subjects
with mild to moderate eosinophilia. Eosinophil donors
were either healthy or had mild allergic rhinitis and
blood was obtained at a time when they were relatively
asymptomatic and off medication. Eosinophils were
isolated by sedimentation with 6% dextran followed by
centrifugation on 1.088 Percoll (Pharmacia, Uppsala,
Sweden) density gradients, as modified from the method
of Hansel 
 
et al
 
.
 
10,11
 
 Cells were further purified by
negative selection using anti-CD16 immunomagnetic
beads and a MACS system (Miltenyi Biotec, Bergisch
Gladbach, Germany). Eosinophils were then suspended
in Hank’s balanced salt solution (HBSS; Life Technolo-
gies, Grand Island, NY, USA) with 1% fetal calf serum
(FCS) in tubes coated with 3% human serum albumin.
The resulting eosinophil purity was more than 99%.
 
Flow cytometric analysis of surface CRTH2
 
This method was used for studying the effect of PGD
 
2
 
on CRTH2 surface expression. Eosinophils were resus-
pended at 1 
 
×
 
 10
 
6
 
 cells/mL in RPMI 1640 (Gibco,
Grand Island, NY, USA) supplemented with 10% FCS
and incubated with various concentrations of PGD
 
2
 
 and
IL-4 (5 ng/mL) or IL-5 (5 ng/mL) or IFN-
 
γ
 
 (100 U/mL) for
3 h at 37
 
°
 
C. Cells were washed twice with phosphate-
buffered saline (PBS) and then stained with biotinylated
antihuman CRTH2 antibody (Ab; BM-16; final concen-
tration 10 
 
µ
 
g/mL; a kind gift from Dr Kinya Nagata and
Dr Hiroyuki Hirai, Bio Medical Laboratories, Saitama,
Japan) and phycoerythrin (PE)-labeled streptavidin. BM16
is not a neutralizing anti-CRTH2 monoclonal antibody
(mAb). Biotinylated rat IgG2a Ab (Becton Dickinson, San
Jose, CA, USA) was used as an isotype-matched control.
Stained cells were analyzed using a flow cytometer
(FACScan; Becton Dickinson Immunocytometry Systems,
San Jose, CA, USA). The expression of CRTH2 is given
as change in mean fluorescence intensity (
 
∆
 
MFI), that is,
the difference in MFI between the sample and the
isotype-matched control.
 
Blockade of CRTH2 internalization on 
eosinophils
 
Inhibition of internalization of surface CRTH2 was
assayed by eosinophils pretreated with 8 
 
µ
 
mol/L phenyl-
arsine oxide (PAO; Sigma-Aldrich, St Louis, MO, USA)
for 5 min and then treated with PGD
 
2
 
 (100 nmol/L) or
IL-5 (5 ng/mL) for 3 h at 37
 
°
 
C. The PAO (8 
 
µ
 
mol/L) was
non-toxic to cells (as assessed by annexin V–fluorescein
isothiocyanate and propidium iodide (PI) staining).
 
Flow cytometric analysis of intracellular or 
whole (intracellular and surface) CRTH2 
expression
 
The method used is a modification of a method
described earlier.
 
12
 
 Briefly, eosinophils were resus-
pended at 1 
 
×
 
 10
 
6
 
 cells/mL in RPMI 1640 supplemented
with 10% FCS and incubated with PGD
 
2
 
 (100 nmol/L)
for 3 h at 37
 
°
 
C. After being washed in PBS, cells were
stained with non-biotinylated BM16 (for intracellular
staining) or biotinylated BM16 (for whole staining) at a
final concentration of 10 
 
µ
 
g/mL in PBS for 30 min at
4
 
°
 
C. Then, 2 mL lysing solution (FACS
 
TM
 
 Lysing Solution;
Becton Dickinson) was added to each sample for 10 min
in the dark at room temperature. After washing, perme-
abilizing solution (FACS
 
TM
 
 Permeabilizing Solution;
Becton Dickinson) was added for 10 min in the dark at
room temperature. After being washed in PBS, cells were
incubated for 30 min with BM16 or isotype-matched Ab
(rat IgG2a) at a final concentration of 30 
 
µ
 
g/mL in PBS
for 30 min at 4
 
°
 
C. Cells were washed with PBS and then
stained with PE-labeled streptavidin for 30 min at 4
 
°
 
C.
Stained cells were analyzed using a flow cytometer.
 
Statistical analysis
 
Data are presented as the mean 
 
±
 
 SD. A one-way 
 
ANOVA
 
with repeated measures was used for comparison of
more than two variables. When the initial 
 
P
 
-value was
less than 0.05, Scheffé’s 
 
F
 
-test was used to determine
the significance between groups. Significance was estab-
lished at 
 
P
 
 < 0.05.
 
R
 
ESULTS
 
Effect of PGD
 
2
 
, IL-4, IL -5 and IFN-
 
γ
 
 on CRTH2 
surface expression
 
We conducted 
 
in vitro
 
 studies aimed at elucidating the
mechanism controlling the expression of CRTH2 on
eosinophils. We selected PGD
 
2
 
, IL-4, IL-5 and IFN-
 
γ
 
 as
possible factors that control CRTH2 expression on eosi-
nophils at allergic inflammatory sites. Prostaglandin D
 
2
 
reduced CRTH2 surface expression on human eosi-
nophils in a dose-dependent manner. The surface
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expression of CRTH2 decreased significantly to 74.7 
 
±
 
5.3, 47.5 
 
± 
 
10.2 and 43.8 
 
±
 
 11.4% (compared with
medium alone) following stimulation with PGD
 
2
 
 at
concentrations of 10, 100 and 1000 nmol/L, respec-
tively (Fig. 1a). Neither IL-4 nor IFN-
 
γ
 
 was able to
significantly modulate the surface expression of CRTH2.
The surface expression of CRTH2 decreased significantly
to 80.1 
 
±
 
 10.8% (compared with medium alone) follow-
ing stimulation with IL-5 (5 ng/mL; Fig. 1b). The dose of
IL-5 used in the present study was chosen on the basis
of results from previous studies showing that IL-5 specif-
ically bound to eosinophils and reached saturation at an
approximate concentration of 1–1.25 nmol/L.
 
13,14
 
  Eosi-
nophils were incubated with PGD
 
2
 
 (100 nmol/L) and
IL-4 (5 ng/mL) or IL-5 (5 ng/mL) or IFN-
 
γ
 
 (100 U/mL)
for 3 h. The reduction in the surface expression of
CRTH2 was not enhanced by the addition of cytokines
compared with eosinophils incubated with PGD
 
2
 
 alone
(Fig. 1c).
 
Effect of PAO pretreatment on PGD
 
2
 
- and 
IL-5-induced CRTH2 downregulation on 
eosinophils
 
To elucidate the mechanism of CRTH2 downregulation
on eosinophils, we pretreated eosinophils with PAO, an
inhibitor of receptor internalization,
 
15
 
 following PGD
 
2
 
or IL-5 treatment. In the present study, PAO inhibited
PGD
 
2
 
- and IL-5-induced CRTH2 downregulation on
human eosinophils (Fig. 2a; Table 1).
 
Effect of PGD
 
2
 
 on whole and intracellular 
CRTH2 expression in human eosinophils
 
Whole CRTH2 expression in PGD
 
2
 
-treated eosinophils
(43.1 
 
±
 
 15.3 
 
∆
 
MFI) was significantly lower than that in
non-treated eosinophils (74.5 
 
±
 
 14.3 
 
∆
 
MFI). In contrast,
there was no difference in the intracellular expression of
CRTH2 before (20.1 
 
±
 
 1.14 
 
∆
 
MFI) and after (20.8 
 
±
4.96 ∆MFI) treatment with PGD2 (Fig. 2b).
DISCUSSION
Prostaglandin D2, a ligand against CRTH2 expressed on
Th2 cells and eosinophils, is produced in the asthmatic
lung and is considered to be an important proinflamma-
tory mediator in allergic disease.16 Because PGD2 was
reported to have chemotactic activity on eosinophils,5,17
CRTH2 expressed on eosinophils attracted interest as a
receptor associated with eosinophil migration to, and
accumulation at, inflammatory sites. CRTH2 is one of
seven transmembrane G-protein-coupled receptors as
well as a chemokine receptor.5 One proposed regu-
latory mechanism for the expression of the seven
Fig. 1 Effect of prostaglandin (PG) D2 and cytokines on the
expression of CRTH2 on human eosinophils. (a) Prostaglandin
D2 induced a dose-dependent downregulation of CRTH2 on
human eosinophils (n = 5; **P < 0.01, ***P < 0.001). (b)
Interleukin (IL)-5 induced a significant downregulation of
CRTH2 on eosinophils; IL-4 and interferon (IFN)-γ did not
change CRTH2 expression on human eosinophils under these
conditions (n = 5; *P < 0.05). (c) Interleukin-4, IL-5 and IFN-γ
did not modify PGD2-induced CRTH2 downregulation on eosi-
nophils (n = 4; **P < 0.01 compared with control). ∆MFI,
change in mean fluorescence intensity.
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transmembrane G-protein-coupled chemokine recep-
tors, such as CCR1, CCR2b, CCR3 and CXCR4, is
ligand-induced internalization.18–21 Cytokines have also
been shown to modulate surface protein expression and
mRNA expression for certain chemokine receptors. For
example, IL-3, IL-5, granulocyte–macrophage colony
stimulating factor (GM-CSF) and IL-4 attenuated the
surface expression of CXCR4.21 In contrast, the regula-
tory mechanism for the expression of CRTH2 is not
well understood. We have observed, in a case of
eosinophilic pneumonia, that the expression of CRTH2
on bronchoalveolar lavage fluid (BALF) eosinophils was
much lower than that of eosinophils in peripheral blood
(∆MFI: 27.5 vs 132.3, respectively; K Hamada et al.,
unpubl. obs.). This observation suggested the pres-
ence of unknown factors produced at the inflammatory
site regulating the expression of CRTH2 on eosinophils.
Moreover, the expression of CCR3 on eosinophils in
BALF was also lower than that on peripheral eosinophils.
Indeed, in the present study, we chose PGD2, IL-4, IL-5
and IFN-γ as possible factors and found that PGD2 and
IL-5 downregulated the expression of CRTH2 on eosi-
nophils. Hirai et al. reported the downregulatory
effect of PGD2 on the expression of CRTH2 on Th2
cells.22 As has been reported for chemokine receptors,
such as CCR1, CCR3 and CXCR4, although it is only
one of several possible explanations, ligand-induced
Fig. 2 Flowcytometric analysis
suggesting internalization and
degradation of CRTH2. Phenyl-
arsine oxide (PAO) pretreatment
inhibited (a) rostaglandin (PG)
D2- and (b) interleukin (IL)-5-
induced CRTH2 downregulation.
Three similar representative
experiments are shown. (c)
Whole CRTH2 expression in
PGD2-treated eosinophils ()
was significantly lower than that
in non-treated eosinophils ().
In contrast, there was no
difference in the intracellular
expression of CRTH2 between
eosinophils treated with () and
without () PGD2 (n = 3;
*P < 0.05).
Table 1 Effect of phenylarsine oxide pretreatment on
prostaglandin D2- and interleukin-5-induced CRTH2 down-
regulation
∆MFI (% control) P
Control 100.00 –
PGD2 40.13 ± 6.57 0.002
PAO + PGD2 68.93 ± 6.58 0.119
IL-5 55.10 ± 21.71 0.018
PAO + IL-5 73.36 ± 14.01 0.213
Data are the mean ± SD. Scheffé’s F-test was used to determine the
significance between groups (n = 3).
FACS analysis was performed to assess surface expression of
CRTH2 on eosinophils.
PGD2, prostaglandin D2; PAO, phenylarsine oxide; IL-5, interleukin-5.
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internalization is the regulatory mechanism responsible
for the downregulation of CRTH2. Indeed, the internal-
ization inhibitor PAO inhibited PGD2- and IL-5-induced
CRTH2 downregulation on human eosinophils. Thus,
the mechanism of CRTH2 downregulation may be
receptor internalization. Interestingly, the intracellular
expression of CRTH2, which was expected to increase
as a result of internalization, was not changed by
PGD2. Unchanged intracellular expression of CRTH2
after PGD2 stimulation suggested the degradation
of CRTH2 following CRTH2 internalization. Ligand-
induced downregulation of receptor expression may
explain the  diminished chemotactic migration after
repetitive stimulation by a certain chemoattractant.23
The decreased expression of CRTH2 on tissue eosi-
nophils may make these cells remain at the site of
allergic inflammation.
In summary, PGD2 and IL-5 reduced CRTH2 expres-
sion on human eosinophils. Further studies are necessary
to elucidate the mechanism and clinical relevance of
PGD2- and IL-5-induced CRTH2 downregulation.
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